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Immunogenicity, safety, and reactogenicity of heterologous 
COVID-19 primary vaccination incorporating mRNA, 
viral-vector, and protein-adjuvant vaccines in the UK 
(Com-COV2): a single-blind, randomised, phase 2, 
non-inferiority trial
Arabella S V Stuart*, Robert H Shaw*, Xinxue Liu*, Melanie Greenland, Parvinder K Aley, Nick J Andrews, J C Cameron, Sue Charlton, 
Elizabeth A Clutterbuck, Andrea M Collins, Tom Darton, Tanya Dinesh, Christopher J A Duncan, Anna England, Saul N Faust, Daniela M Ferreira, 
Adam Finn, Anna L Goodman, Christopher A Green, Bassam Hallis, Paul T Heath, Helen Hill, Bryn M Horsington, Teresa Lambe, Rajeka Lazarus, 
Vincenzo Libri, Patrick J Lillie, Yama F Mujadidi, Ruth Payne, Emma L Plested, Samuel Provstgaard-Morys, Maheshi N Ramasamy, Mary Ramsay, 
Robert C Read, Hannah Robinson, Gavin R Screaton, Nisha Singh, David P J Turner, Paul J Turner, Iason Vichos, Rachel White, 
Jonathan S Nguyen-Van-Tam D M, Matthew D Snape, and the Com-COV2 Study Group†
Summary
Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate 
rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 
[ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer–BioNTech, and mRNA-1273 [m1273], Moderna) and 
a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).
Methods Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously 
immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three 
and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8–12 weeks after the first dose) with 
the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum 
SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days 
after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI. The primary 
analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all 
participants who received a dose of study vaccine. The trial is registered with ISRCTN, number 27841311.
Findings Between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of 
a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric 
mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 
(20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) 
was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 
98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd. In BNT-
primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but 
not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a 
GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with 
BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse 
events, none considered related to immunisation.
Interpretation Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity 
compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation 
following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of 
such schedules for vaccine certification.
Funding UK Vaccine Task Force, Coalition for Epidemic Preparedness Innovations (CEPI), and National Institute for 
Health Research. NVX vaccine was supplied for use in the trial by Novavax.
Copyright © 2021 Elsevier Ltd. All rights reserved.
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Introduction
The COVID-19 pandemic that began in 2019 has resulted 
in more than 5 million deaths to date.1 As of Oct 20, 2021, 
over 3 billion people globally have received at least one 
dose of a SARS-COV-2 vaccine, but only 2·8% of people 
in low-income countries.1 Although there are now 
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24 different vaccines approved worldwide, manufacturing 
issues, raw material shortages, and surges in infection 
have led to supply chain disruption and delays.2–4 The 
emergence of new safety concerns with available vaccines 
led to changes in vaccine deployment policy. In early 2021, 
multiple countries implemented age restrictions for the 
ChAdOx1 n-CoV-19 vaccine (AstraZeneca, hereafter 
referred to as ChAd) after the emergence of vaccine-
induced thrombocytopenia and thrombosis, and recent 
pauses in immunisation of young people with mRNA 
vaccines due to concerns about myocarditis.5–8 Such 
changes have disrupted roll-out plans, and have the 
potential to do so in future. Additionally, concerns about 
waning vaccine immunity, and the potential for existing 
schedules to protect against new SARS-CoV-2 variants of 
concern have led to questions on the optimisation of 
vaccine schedules.9
Heterologous prime-boost COVID-19 vaccination 
might be useful in responding to these challenges. Many 
national immunisation advisory groups implemented 
this strategy on a pragmatic basis following ChAd-related 
vaccine-induced thrombocytopenia and thrombosis 
events before evidence had accrued.10–12 Since then, a 
number of studies have shown an acceptable short-term 
safety profile of ChAd and BNT162b2 (Pfizer–BioNTech, 
hereafter referred to as BNT) heterologous vaccination, 
although with some transient increased reactogenicity.13–17 
There is accruing evidence that the use of an mRNA 
boost after adenoviral-vector prime might enhance 
humoral and cellular responses against SARS-CoV-2, 
and that this response translates to efficacy against 
COVID-19.8,14–16,18–29 The only other available data regarding 
heterologous schedules comes from preprints that 
suggest that adenoviral vaccines might be an effective 
boost for inactivated whole-virion prime.30,31
 To date, there are no published data from randomised 
controlled trials examining the immunogenicity and 
safety of heterologous schedules of primary course 
COVID-19 vaccination with mixed mRNA, and none 
examining regimes containing a protein-subunit vaccine. 
NVX-CoV2373 (Novavax, hereafter referred to as NVX), a 
Matrix-M adjuvanted recombinant nanoparticle spike 
protein vaccine, has shown safety and efficacy in phase 3 
trials and has been submitted to multiple regulatory 
agencies, including WHO, for licensing.32 This vaccine 
can be transported and stored at standard refrigeration 
temperatures, making it particularly suitable for 
deployment in low-resource settings.33 An mRNA vaccine 
mRNA-1273 (Moderna, hereafter referred to as m1273) 
has also shown high efficacy in clinical trials, with an 
acceptable safety profile, although with appreciable 
reactogenicity after second dose.34
We have previously reported on the preliminary results 
of the Com-COV study, a randomised controlled trial of 
Research in context
Evidence before this study
Most high-income countries have now vaccinated their adult 
populations with a primary course of COVID-19 vaccine, but 
deployment remains low across lower income regions. 
Heterologous prime-boost schedules are a measure that could 
enhance deployment flexibility and improve access to vaccines. 
Evidence to support the use of mixed schedules is rapidly 
evolving. We searched PubMed for articles published between 
database inception and Oct 20, 2021 using the terms “(COVID) 
AND (heterologous) AND (vaccin*) NOT (BCG)” with no language 
restrictions. An additional search was done of the medRxiv 
preprint server. There are few randomised controlled trials 
examining heterologous schedules, but many observational 
studies. Heterologous schedules studied included:  ChAdOx1 
nCoV-19 (ChAd)/BNT162b2 (BNT), BNT/ChAd, ChAd/
mRNA-1273, Ad26/Ad5, ChAd/BBV152, Coronavac/ChAd, 
Coronavac/Convidecia, and Ad26/BNT. Where a homologous 
comparator was included, reactogenicity appeared increased in 
heterologous boost, but was tolerated. There were no safety 
concerns identified in any study. Heterologous schedules were 
immunogenic, with mRNA boost after ChAd prime inducing 
higher concentrations of neutralising antibodies when compared 
with homologous ChAd. mRNA boost after ChAd prime induced 
a T-cell response above that of homologous comparators. 
Adenoviral-vectored boost after inactivated prime appears to 
enhance immunogenicity over that of inactivated prime-boost.
Added value of this study
These data are the first from a randomised controlled 
trial of COVID-19 vaccines of heterologous mRNA boost and 
protein-subunit boost. We have shown that reactogenicity at 
boost is consistently increased in heterologous versus 
homologous schedules of ChAd and mRNA vaccines, but not 
increased by NVX-CoV2373 (NVX) boost after ChAd or BNT 
prime. mRNA-1273 as a heterologous boost after ChAd or BNT 
prime induces a higher binding and neutralising antibody 
response than either homologous schedule. Heterologous boost 
with NVX after ChAd prime was superior to homologous ChAd 
for induction of humoral and cellular immunity. NVX after BNT 
prime did not meet non-inferiority criteria for binding 
antibodies when compared with homologous BNT; however, 
in a non-randomised comparison, binding antibody 
concentrations were still well above the geometric mean 
concentration observed following ChAd/ChAd. Decrements in 
neutralising antibody responses to beta and delta variants of 
concern were largely conserved across schedules, whereas T-cell 
responses were not affected.
Implications of all the available evidence
This study adds to the body of evidence that heterologous 
COVID-19 vaccination is safe, tolerated, and immunogenic. 
Flexibility of schedules should be considered to improve 
access to COVID-19 vaccination globally.
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ChAd and BNT heterologous vaccination.8,13 Here, we 
present findings from the related Com-COV2 study, a non-
inferiority randomised controlled trial examining safety, 
reactogenicity, and immunogenicity of hetero logous 
COVID-19 regimens including m1273 and NVX as boost 
vaccines for people who received a first dose of ChAd or 
BNT in the community COVID-19 vaccination programme 
in the UK, given after the prime at 8–12 weeks.
Methods
Study design
Com-COV2 is a UK multicentre, single-blinded, 
randomised, phase 2, non-inferiority study, investigating 
the safety, reactogenicity, and immunogenicity of 
hetero logous boost COVID-19 vaccine schedules. 
Recruitment occurred at nine National Health Service 
and academic institutions in England (appendix 
p 4). The trial was reviewed and approved by the 
South-Central Berkshire Research Ethics Committee 
(21/SC/0119), the University of Oxford, and the 
Medicines and Healthcare products Regulatory Agency.
Most participants were enrolled into the general cohort 
while a subset (n=150, selected on the basis of site capacity 
and participant availability) were enrolled into an immuno-
logy cohort that had mucosal and salivary samples 
collected, along with two additional blood tests to explore 
the kinetics of the immune responses.
We report the primary endpoint results, and reacto-
genicity profile from the day 28 visit. Safety data were 
collected up until Oct 5, 2021. The protocol is provided in 
the appendix (pp 45–123), and online.
Participants
The study inclusion criteria were being aged 50 years 
or older and having received a single dose of either 
ChAd or BNT by routine immunisation 8–12 weeks 
earlier. Important exclusion criteria were history of 
confirmed SARS-CoV-2 infection, comorbidities that 
were considered severe or poorly controlled, anaphylaxis 
or allergy to a vaccine component, pregnancy, or intent to 
conceive, breastfeeding, and use of anticoagulants. Full 
details of the inclusion and exclusion criteria can be 
found in the protocol (appendix pp 69–71).
Randomisation and masking
Computer generated randomisation lists were prepared by 
the study statistician. Participants were randomised (1:1:1) 
to receive a single dose of either the same vaccine as their 
prime dose (BNT or ChAd homologous schedule), m1273, 
or NVX (heterologous schedules).
Randomisation was done by random block sizes of 
three and six. Randomisation was stratified by study site, 
cohort (immunology or general), and prime vaccine 
(ChAd/BNT). Clinical research nurses who were not 
involved in endpoint evaluation did the randomisation 
using REDCap version 10.6.13 and prepared and 
administered the vaccine.
Participants were masked to boost vaccine allocation at 
enrolment. Blinding was maintained by completing pages 
and by preparing vaccines out of sight of participants, and 
use of the same syringe type across vaccines, with the 
drawn volume concealed by applying a masking tape. 
Following the introduction of COVID-19 vaccine 
certification in the UK, the study was amended on 
June 21, 2021, to allow individual participant unblinding 
where necessary to prevent disadvantage in accessing 
facilities or travel. This took place after all participants had 
completed the 28 day postvaccination diary monitoring 
period. Staff involved in study delivery, including in the 
assessment of adverse events, were aware of vaccine 
allocation. Laboratory staff processing the immunology 
samples remained blinded to vaccine allocation.
Procedures
Participants meeting inclusion and exclusion criteria at 
the online screening (and additional subsequent 
telephone screening for some participants) were invited 
to attend a screening and enrolment visit (day 0). 
Participants who met final eligibility criteria and provided 
written informed consent were randomly assigned to a 
study group and vaccinated at the day 0 visit. Baseline 
haematological and biochemical blood tests were taken 
before vaccination at day 0.
Four vaccines were used in this study. ChAd was given as 
a 0·5 mL intramuscular injection into the upper arm. BNT 
was given as a 0·3 mL intramuscular injection into the 
upper arm. m1273 was given as a 0·5 mL intramuscular 
injection into the upper arm, and NVX as a 0·5 mL 
intramuscular dose injection into the upper arm.
Participants were observed for at least 15 min after 
vaccination. During the day 0 visit, participants were 
given an oral thermometer, tape measure, and diary card 
(electronic or paper) to record solicited, unsolicited, and 
medically attended adverse events with instructions. 
Study-site physicians reviewed the diary card regularly to 
identify, clinically action, and record adverse events, 
adverse events of special interest, and serious adverse 
events, with additional recording of events that were not 
entered into the diaries collected in person at study visits. 
The follow-up visit schedule can be found in the protocol 
(appendix pp 116–17).
Participants were instructed to notify trial teams if they 
received a positive SARS-CoV-2 test in the community. 
They were then invited for a study visit to allow for 
clinical assessment, collection of blood samples, and a 
nasopharyngeal swab, and were asked to complete a 
COVID-19 symptom diary for 7 days.
Sera were analysed at Nexelis (Laval, QC, Canada) to 
determine SARS-CoV-2 anti-spike IgG concentrations by 
ELISA (reported as ELISA laboratory units [ELU]/mL) and 
the 50% neutralising antibody titre (NT50) for SARS-CoV-2 
pseudotype virus neutralisation assay, using a vesicular 
stomatitis virus backbone adapted to bear the 2019-nCOV 
SARS-CoV-2 spike protein.35 The conversion factors 
For the protocol online see 
https://comcovstudy.org.uk
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to international standard units can be found in the 
appendix (pp 3–4). Sera from day 0 were analysed at Porton 
Down, Public Health England, by ECLIA (Cobas platform, 
Roche Diagnostics) to determine anti-SARS-CoV-2 nucleo-
capsid IgG status (reported as negative if below a cutoff 
index of 1·0). The samples from the immunology cohort 
(n=25) were also tested at Porton Down, UK Health 
Security Agency to measure the normalised 80% 
neutralising antibody titre (NT80) for live SARS-CoV-2 
virus (lineage Victoria/01/2020) by micro neutralisation 
assays.35  For participants from five of nine selected sites, 
IFN-γ secreting T cells specific to whole spike protein 
epitopes, designed based on the Wuhan-Hu-1 sequence 
(YP_009724390.1), were detected using a modified 
T-SPOT-Discovery test done at Oxford Immunotec 
(Abingdon, UK) within 32 h of venepuncture, using the 
addition of T-Cell Xtend reagent to extend peripheral blood 
mononuclear cell (PBMC) survival.  Participants at the 
other four sites did not have these taken as their sites were 
too far from the processing laboratory to enable sample 
integrity. T-cell frequencies were reported as spot forming 
cells (SFC) per 250 000 PBMCs with a lower limit of 
detection of one in 250 000 PBMCs. Intracellular cytokine 
staining was done on cryopreserved PBMCs, stimulated for 
16 h with SARS-CoV-2 antigens (based on the Wuhan-Hu-1 
sequence). Cells were stained with viability dye and 
fluorochrome-conjugated antibodies to CD3, CD4, and 
CD8 and further stained with fluorochrome-conjugated 
antibodies specific to IFN-γ, TNF-α, IL-2, IL-4, IL-5, and 
IL-13. Data are presented as percentage of CD4 or CD8 
T cells expressing specific cytokines.36
Samples collected at day 28 after boost immunisation 
from a subgroup of seronegative participants (roughly 
50 per arm) were selected pragmatically to test immun-
ogenicity against Victoria/01/2020 (representative of wild-
type), beta, and delta variants. Cryopreserved samples were 
tested against full spike protein from these variants 
using ELISpot at Oxford Immunotec. Microneutralisation 
assays to determine 50% focus reduction neutralisation 
titres (FRNT50) for live SARS-CoV-2 virus lineages 
(Victoria/01/2020, beta variant B.1.351, delta variant 
B.1.617.1) were done at the University of Oxford, Oxford, 
UK. The reduction in the number of infected foci is 
compared with a negative control well without an antibody.37
Outcomes
The primary outcome was non-inferiority of serum 
SARS-CoV-2 anti-spike IgG concentration 28 days after 
heterologous boost in comparison with homologous 
boost (the geometric mean ratio [GMR]) in participants 
who were seronegative for SARS CoV-2 nucleocapsid IgG 
at enrolment.
Secondary outcomes included safety and reactogenicity, 
measured through local and systemic solicited adverse 
events for 7 days after the boost, unsolicited adverse events 
for 28 days after the boost, medically attended adverse 
events up to 3 months after boost, and adverse events of 
special interest and serious adverse events throughout the 
study. Haematological and biochemical blood parameters 
were measured at day 0 and day 28 after the boost for all 
participants, and additionally at day 7 for those in the 
immunology cohort. Full definitions of safety outcomes 
can be found in the protocol (appendix pp 95–103). 
Immunological secondary outcomes include kinetics of 
SARS-CoV-2 anti-spike binding IgG concentration, 
live virus neutralisation titres, pseudotype virus neu-
tralisation titres, cellular responses (measured by IFNγ 
ELISpot) in peripheral blood, and intracellular cytokines. 
The full list of outcome measures can be found in the 
protocol (appendix pp 66–67).
Statistical analysis
The primary analysis of SARS-CoV-2 anti-spike IgG was 
carried out on a per-protocol basis. The per-protocol 
population consisted of participants who were 
seronegative for SARS-CoV-2 at baseline (defined by anti-
nucleocapsid IgG negativity), had no confirmed 
SARS-CoV-2 infection within 14 days after boost 
vaccination, received the study vaccine as randomly 
assigned, had primary endpoint data available, and had no 
protocol deviations, whereas the modified intention-to-
treat (mITT) population included the per-protocol 
population and participants with protocol deviations. The 
GMR was calculated as the antilogarithm of the difference 
between the mean of the log10 transformed titre in the 
heterologous arms and the corresponding homologous 
arm as the reference adjusting for study site and cohort 
(general or immunology) in the linear regression model. 
Results are presented separately for participants primed 
with ChAd and BNT in the community. We did four 
primary comparisons and therefore we presented one-
sided 98·75% CIs to adjust for multiple testing for the 
primary outcome. Non-inferiority of a heterologous arm 
to its corresponding homologous arm was concluded if 
the lower 98·75% CI of a GMR lay above the non-inferiority 
margin of 0·63. This margin was chosen after discussion 
with policy makers and regulatory agencies to allow a 
sample size consistent with rapid study delivery, while still 
being close to the WHO criterion of 0·67 for licensing of 
new vaccines.38 We also presented geometric means, 
adjusted GMRs, and corresponding two-sided 95% CIs in 
the mITT population. A heterologous arm was considered 
superior to its homologous arm if the lower limit of the 
two-sided 95% CI lies above one, and the homologous 
boost arm was superior if the upper limit of the two-sided 
95% CI lies below one. The analyses for secondary 
immunological outcome were also carried out among the 
mITT population. For all immunological outcomes, 
censored data reported as below the lower limit of 
detection or lower limit of quantification were imputed 
with a value equal to half of the threshold before tran-
sformation. Correlations between different immunological 
outcomes were evaluated by Pearson correlation coe-
fficients. Participants who received at least one dose of the 
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study vaccines were included in the safety analysis. The 
proportion of participants with at least one safety event 
was reported by vaccine schedule.
The sample size calculation assumed a non-inferiority 
margin of a 0·63 fold difference between the geometric 
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Figure 1: Trial profile
BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. m1273=mRNA-1273 vaccine, Moderna. NVX=NVX-CoV2373 vaccine, Novavax. 
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homologous boost arms, a SD of 0·456 on log10 scale, and 
a true difference in GMC on log10 scale of zero. The study 
needed to recruit 175 participants in each arm to achieve 
90% power at a one-sided 1·25% significance level, after 
adjusting for an attrition rate of 25% due to baseline 
SARS-CoV-2 seropositivity or loss to follow-up. Statistical 
analyses were done using R version 4.1.1 and SAS 
version 9.4.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
From April 19 to May 14, 2021, 1174 participants across 
nine study sites in England were screened, with a total of 
1072 enrolled and randomly assigned to a study group: 
921 to the general cohort and 151 to the immunology 
cohort (figure 1).
Recruitment was stratified by community prime 
vaccines, with 540 participants having received ChAd and 
532 BNT. Study site recruitment by community prime is 
presented in the appendix (p 4). All participants were 
immunised.
The median age of participants primed with ChAd was 
63 years (range 50–75 years), 241 (45%) were female, and 
50 (9%) were from minority ethnicities. In participants 
primed with BNT, the median age was 62 years (range 
50–78 years), 210 (40%) were female, and 28 (5%) from 
minority ethnicities (table 1). There were higher rates of 
cardiovascular, respiratory, and diabetic comorbidity in the 
BNT primed groups; reflective of the earlier availa bility of 
BNT in the UK and vaccination prioritisation in the initial 
phases of the national vaccine roll-out. Median prime-
boost interval was 9·4 (range 4·7–12·0) weeks for the 
ChAd community-prime group, and 9·6 (8·0–12·0) weeks 
for the BNT community-prime group (table 1).
Within each prime group, characteristics were 
well balanced between the three randomised arms, 
except for a male predominance in the BNT/NVX 
group (34% female; table 1). At baseline, 54 (5%) of 
1072 participants were positive for anti-nucleocapsid IgG 
(cutoff index ≥1·0), with a range of 4–6% in the ChAd-
primed groups and 3–7% in the BNT-primed groups 
(figure 1).
Participants who received a community prime 
with ChAd had a SARS-CoV-2 anti-spike IgG GMC at 
28 days of 20 114 ELU/mL (95% CI 18 160 to 22 279) in 
the m1273 group, 5597 ELU/mL (4756 to 6586) in the 
NVX group, and 1971 ELU/mL (1718 to 2262) in the ChAd 
homologous group (per-protocol analysis; table 2). 
GMRs in the per-protocol population were 10·2 
(one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 
(2·2 to ∞) for ChAd/NVX when compared with ChAd/
ChAd, with lower limits of both the CIs above the non-
inferiority margin. Similar GMRs were observed in the 
mITT population, and the SARS-CoV-2 anti-spike IgG 
Prime with ChAd Prime with BNT
ChAd (n=180) m1273 (n=181) NVX (n=179) Overall (n=540) BNT (n=175) m1273 (n=177) NVX (n=180) Overall (n=532)
Age
Mean (SD) 63·0 (5·51) 63·3 (5·55) 63·1 (5·76) 63·2 (5·60) 61·9 (5·37) 62·0 (5·92) 62·2 (5·56) 62·0 (5·61)
Median (range) 64·4 (50·1–74·2) 64·1 (50·2–74·4) 64·2 (50·1–74·6) 64·2 (50·1–74·6) 62·3 (50·4–77·1) 62·4 (50·0–77·7) 62·7 (50·2–78·1) 62·4 (50·0–78·1)
Gender
Female 87 (48%) 80 (44%) 74 (41%) 241 (45%) 80 (46%) 68 (38%) 62 (34%) 210 (40%)
Male 93 (52%) 101 (56%) 105 (59%) 299 (55%) 95 (54%) 109 (62%) 118 (66%) 322 (61%)
Ethnicity
White 169 (94%) 159 (88%) 162 (91%) 490 (91%) 166 (95%) 166 (94%) 172 (96%) 504 (95%)
Black 1 (1%) 1 (1%) 3 (2%) 5 (1%) 3 (2%) 2 (1%) 3 (2%) 8 (2%)
Asian 4 (2%) 11 (6%) 9 (5%) 24 (4%) 3 (2%) 5 (3%) 2 (1%) 10 (2%)
Mixed 3 (2%) 7 (4%) 3 (2%) 13 (2%) 1 (1%) 1 (1%) 2 (1%) 4 (1%)
Other 3 (2%) 3 (2%) 2 (1%) 8 (2%) 2 (1%) 3 (2%) 1 (1%) 6 (1%)
Comorbidities*
Cardiovascular 49 (27%) 55 (30%) 40 (22%) 144 (27%) 63 (36%) 46 (26%) 57 (32%) 166 (31%)
Respiratory 15 (8%) 18 (10%) 19 (11%) 52 (10%) 30 (17%) 34 (19%) 31 (17%) 95 (18%)
Diabetes 9 (5%) 10 (6%) 14 (8%) 33 (6%) 22 (13%) 21 (12%) 24 (13%) 67 (13%)
Prime-boost interval (weeks)
Mean (SD) 9·4 (0·96) 9·5 (0·95) 9·5 (1·01) 9·5 (0·97) 9·5 (0·98) 9·5 (0·95) 9·6 (0·96) 9·5 (0·96)
Median (range) 9·4 (8·0–12·0) 9·4 (8·0–12·0) 9·4 (4·7†–11·9) 9·4 (4·7–12·0) 9·6 (8·0–11·9) 9·4 (8·0–12·0) 9·6 (8·0–11·9) 9·6 (8·0–12·0)
Data are n (%), mean (SD), or median (range). BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. m1273=mRNA-1273 vaccine, Moderna. NVX=NVXCoV2373 vaccine, 
Novavax. *Comorbidities were self-reported by participants, with review by study team doctor for assessment of severity. General practitioner confirmation was sought where needed. Included severities were 
those classified as mild, moderate, or well controlled. †Single participant boosted in error at 33 days, protocol deviation. 
Table 1: Baseline characteristics by study arm
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response to ChAd/m1273 and ChAd/NVX were both 
statistically superior to that of homologous ChAd/ChAd 
(table 2).
In those who received BNT community prime, 
anti-spike IgG GMC was 22 978 ELU/mL (95% CI 
20 597 to 25 636) in the m1273 group, 16 929 ELU/mL 
(15 025 to 19 075) in the BNT homologous group, and 
8874 ELU/mL (7391 to 10 654) in the NVX group 
(per-protocol analysis, table 2). The BNT/m1273 group 
GMR was 1·3 (one-sided 98·75% CI 1·1 to ∞), with the 
lower limit of the CI above the non-inferiority margin, 
and was statistically superior to BNT/BNT. Although 
BNT/NVX did not meet the non-inferiority criterion at 0·5 
(one-sided 98·75% CI 0·4 to ∞) there was an 18-fold rise 
(95% CI 15 to 21) from baseline (appendix pp 8–10). 
Similar results were reported for the mITT analysis 
(table 2).
In the mITT population, the GMRs between the live 
virus neutralising antibody titres (normalised FRNT50) 
against the Victoria strain, the live virus neutralising 
antibody titres (normalised NT80 by microneutralisation 
assays), and the pseudotype virus neutralising (NT50) 
antibody titres from the mITT analysis at 28 days after 
boost are broadly consistent with those of binding 
antibodies (table 2).
Cellular responses by T-cell ELISpot for ChAd 
community-primed participants were greatest in those 
boosted with NVX at 190 SFC per million PBMCs (95% CI 
159–227), with a GMR of 4·8 (3·6–6·6) compared with 
participants receiving homologous ChAd (45 SFC 
per million PBMCs, 34–61). For those boosted with m1273 
these respective values were 148 SFC per million PBMCs 
(118–187) and a GMR of 3·5 (2·5–4·8; table 2).
In BNT community-primed groups, cellular responses 
by T-cell ELISpot were higher in those receiving m1273 at 
76 SFC per million PBMCs (95% CI 58–99) than in the 
homologous boost group at 49 SFC per million PBMCs 
(39–63); however, the GMC for NVX boost was below 
Prime with ChAd Prime with BNT
ChAd/ChAd ChAd/m1273 ChAd/NVX BNT/BNT BNT/m1273 BNT/NVX
Per-protocol analysis
SARS-CoV-2 anti-spike IgG, ELU/mL
n/N 163/164 162/162 158/160 159/163 153/154 163/166
GMC 1971 (1718 to 2262) 20 114 (18 160 to 22 279) 5597 (4756 to 6586) 16 929 (15 025 to 19 075) 22 978 (20 597 to 25 636 8874 (7391 to 10 654)
GMR* Ref 10·2 (8·4 to ∞) 2·8 (2·2 to ∞) Ref 1·3 (1·1 to ∞) 0·5 (0·4 to ∞)
Modified intention-to-treat analysis
SARS-CoV-2 anti-spike IgG, ELU/mL
n/N 170/171 167/167 165/167 163/167 163/164 169/172
GMC 1959 (1704 to 2253) 20 360 (18 411 to 22 517) 5440 (4632 to 6390) 16 838 (14 985 to 18 921) 23 187 (20 891 to 25 735) 8913 (7464 to 10 644)
GMR* Ref 10·5 (8·9 to 12·3) 2·8 (2·2 to 3·4) Ref 1·3 (1·2 to 1·6) 0·53 (0·43 to 0·65)
Live virus neutralising antibody (Victoria†), FRNT50
n/N 47/171 48/167 51/167 46/167 48/164 49/172
GMC 109 (70 to 168) 1684 (1313 to 2162) 432 (301 to 618) 1501 (1188 to 1896) 1883 (1546 to 2294) 1109 (805 to 1529)
GMR* Ref 16·9 (10·1 to 28·0) 4·2 (2·4 to 7·2) Ref 1·3 (1·0 to 1·8) 0·8 (0·6 to 1·2)
Live virus neutralising antibody (Victoria†), normalised NT80
n/N 19/171 18/167 20/167 17/167 19/164 21/172
GMC 331 (213 to 514) 2244 (1737 to 2901) 630 (398 to 997) 3216 (2336 to 4427) 3252 (2416 to 4376) 868 (494 to 1527)
GMR* Ref 7·5 (4·4 to 12·7) 2·0 (1·0 to 3·9) Ref 1·0 (0·6 to 1·6) 0·3 (0·1 to 0·6)
Pseudotype virus neutralising antibody, NT50
n/N 169/171 154/167 158/167 159/167 157/164 163/172
GMC 132 (113 to 154) 1358 (1182 to 1562) 473 (399 to 561) 883 (751 to 1039) 1260 (1106 to 1436) 787 (631 to 981)
GMR* Ref 10·0 (8·1 to 12·3) 3·4 (2·7 to 4·3) Ref 1·4 (1·2 to 1·7) 0·9 (0·7 to 1·2)
Cellular response (wild-type), SFC per million PBMCs‡
n/N 95/171 101/167 98/167 96/167 98/164 102/172
GMC 45 (34 to 61) 148 (118 to 187) 190 (159 to 227) 49 (39 to 63) 76 (58 to 99) 29 (22 to 38)
GMR* Ref 3·5 (2·5 to 4·8) 4·8 (3·6 to 6·6) Ref 1·5 (1·1 to 2·2) 0·6 (0·4 to 0·9)
In the per-protocol analysis, data are n/N, GMC (95% CI), and GMR (98·75% CI); in the modified intention-to-treat analysis, data are n/N, GMC (95% CI), and GMR (95% CI). BNT=BNT162b2 vaccine, 
Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA laboratory units. FRNT50=50% focus reduction neutralising antibody titre. GMC=geometric mean concentration. GMR=geometric 
mean ratio. m1273=mRNA−1273 vaccine, Moderna. NT80=80% neutralising antibody titre. NVX=NVXCoV2373 vaccine, Novavax. NT50=50% neutralising antibody titre. SFC=spot-forming cells. PBMC=peripheral 
blood mononuclear cell. *GMRs were adjusted for randomisation stratification variables, including study site and cohort, with one-sided 98·75% CIs in per-protocol analyses and were further adjusted for interval 
between first and second dose and baseline immunogenicity, with two-sided 95% CIs in the modified intention-to-treat analyses; non-inferiority margin is 0·63. †A Wuhan-related strain isolated early in the 
pandemic from Australia. ‡Cellular response data were available in around 60% of sites, the rest of the study sites did not collect plasma samples due to logistical challenges. 
Table 2: Summary of immunogenicity between heterologous and homologous prime-boost schedules at 28 days post boost
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that of the homologous boost at 29 SFC per million 
PBMCs (22–38; table 2).
Correlations between cellular and humoral responses 
show a moderate correlation for the ChAd/ChAd group 
(correlation coefficient of 0·46), and weak correlation 
(Pearson correlation coefficients <0·3) for all other 
schedules (figure 2A). There is a strong correlation 
between live neutralising assays done at national 
reference and local laboratories (figure 2D).
In the modified intention-to-treat population, the 
GMCs of anti-spike IgG at baseline were 381 (95% CI 
347–418) and 526 (480–577) in the populations previously 
immunised with ChAd and BNT, respectively. While an 
increase in antibody concentrations at day 7 compared 
with baseline was observed in all groups, these tended to 
remain stable or decrease across all groups by day 28 
except those receiving an NVX-CoV2373 boost, where 
there was a further increase from day 7 to day 28 (figure 3, 
appendix pp 6–9). 
With regard to cellular responses, participants who had 
received a community prime with ChAd had numerically 
higher baseline frequencies than did the BNT groups; 
responses peaked in all groups at day 14 but were 
maintained above baseline at day 28 (figure 3B). 
Responses of intracellular cytokines to SARS-COV-2 
spike peptides by flow cytometry at day 0 and 14 after 
boost were similar across groups, with a predominantly 
T-helper-1 cell response (appendix pp 11–14).
In ChAd-primed groups, live virus neutralising 
antibody titres (FRNT50) were reduced according to 
Figure 2: Correlation in the modified intention-to-treat population
(A) SARS-CoV-2 anti-spike IgG and cellular response by IFN-γ ELISpot (the subset with cellular data only, n=582), (B) SARS-CoV-2 anti-spike IgG and live virus 
neutralising antibodies (the subset with live virus neutralising antibodies data only, n=289), (C) live virus neutralising antibodies and cellular response by IFN-γ 
ELISpot at 28 days after boost (the subset with live virus neutralising antibodies data only, n=289), (D) live virus neutralising antibodies tested at University of Oxford 
and those tested at Porton Down, UK Health Security Agency (the immunology cohort, n=123). Ellipses show the 95% CI for different vaccine schedules assuming 
multivariate normal distributions. Pearson correlation coefficients (95% CI) are presented for each vaccine schedule. BNT=BNT162b2 vaccine, Pfizer–BioNTech. 
ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA laboratory units. FRNT50=50% focus reduction neutralising antibody titre. m1273=mRNA-1273 vaccine, 
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point estimates across all groups for beta and delta 
variants, relative to Victoria, with the greatest decrement 
noted for beta (table 3, appendix pp 15–17). However, 
both heterologous groups maintained numerically 
higher titres than ChAd/ChAd, with the highest titres in 
ChAd/m1273 recipients, with GMRs of 15·8 (95% CI 
9·6–26·1) against the beta variant and 17·4 (10·2–29·5) 
against the delta variant. Similarly, in BNT-primed 
groups, live virus neutralising antibody titres (FRNT50) 
across groups were numerically lower against beta and 
delta variants than to Victoria (table 3). There was no 
evidence of a difference in neutralising activity against 
Victoria, beta, and delta variants between the BNT-
primed groups. Across all groups, little difference was 
noted in cellular responses to variants (table 3, 
appendix p 15).
Local and systemic reactions were more frequent 
after m1273 boost vaccination compared with the 
homologous boost groups, with feverishness reported by 
60 (33%) of 181 recipients of ChAd/m1273 compared 
with nine (5%) of 176 recipients of ChAd/ChAd 
(difference 28%, 95% CI 20–36), and by 39 (22%) of 
176 recipients of BNT/m1273, compared with 16 (9%) of 
175 recipients of BNT/BNT (13%, 5–21; figure 4). Similar 
increases were observed for chills, fatigue, fever, 
headache, joint pain, malaise, muscle ache, and nausea 
(figure 4). Most of the increase in reactogenicity was 
observed within the 48 h after immunisation (appendix 
pp 18–19).
By contrast, for NVX recipients, similar patterns were 
observed in systemic reactogenicity compared with the 
homologous study schedules. Local reactions were 
generally less frequent for NVX recipients, for example a 
difference in injection site pain of –49% (95% CI 
–50 to –30) for BNT/NVX compared with BNT/BNT. 
Paracetamol use mirrored the profile of systemic 
reactogenicity (appendix p 20).
Between enrolment and Oct 5, 2021, there were 
589 adverse events in 357 participants (appendix p 21). 
Numbers of adverse events were similar across vaccine 
groups. Descriptions of all non-serious adverse events of 
grade 3 or worse are presented in the appendix (pp 22–25). 
There were five adverse events of special interest 
(excluding SARS-CoV-2 and COVID-19 events) and one 
deemed possibly related to study vaccination (eosinophilia, 
grade 2 severity; appendix p 26).
18 participants tested positive for SARS-CoV-2 or had a 
COVID-19 episode after enrolment (appendix pp 26–28). 
All cases occurred at least 2 months after a boost, 
coinciding with an epidemiological surge of infection 
nationally. A single participant was hospitalised but did 
not require invasive ventilation (appendix pp 28–30). 
There were 15 serious adverse events, none of which was 
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Figure 3: Kinetics of immunogenicity by vaccine schedule
Cellular response data were available in around 60% of sites, the other study sites did not collect plasma samples due to logistical challenges; data presented at day 7 
and day 14 were from the immunology cohort only. Data presented from day 0 and day 28 are for all participants in the modified intention-to-treat-population. 
Boxplots represent the median and 25th and 75th percentiles; the whiskers extend up to the largest value, not greater than 1·5 times the IQR beyond the box. 
(A) Anti-spike IgG and (B) T-cell response. BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA laboratory units. 
m1273=mRNA−1273 vaccine, Moderna. NVX=NVXCoV2373 vaccine, Novavax. PBMCs=peripheral blood mononuclear cells. SFC=spot-forming cells.
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Biochemical and haematological blood results were 
taken at enrolment, day 7, and day 28 after boost and 
graded by modified US Food and Drug Administration 
toxicity scale (appendix pp 31–32, 120). There were no 
notable differences in biochemical adverse events 
between groups, with some minor variations reported 
in white blood cell indices. A single participant had 
grade 3 neutropenia at enrolment and day 7, which 
progressed to grade 4 at day 28 and was reported as an 
unrelated serious adverse event.
Discussion
Findings from this trial demonstrate that the immuno-
genicity of heterologous boost with m1273 following 
community prime with ChAd or BNT was non-inferior to 
the homologous-boost schedule. When heterologous boost 
was with NVX, only those primed with ChAd had titres of 
SARS-CoV-2 anti-spike IgG that were non-inferior to the 
homologous schedule, whereas BNT/NVX did not meet 
the non-inferiority threshold against homologous BNT. 
Nevertheless, within the limitations of comparing between 
non-randomised cohorts, SARS-CoV-2 anti-spike IgG 
titres induced by BNT/NVX were still above that of 
homologous ChAd, a schedule with demonstrated 
effectiveness of 65–70% against symptomatic SARS-CoV-2 
infection and over 90% against hospitalisation and death.39 
Additionally, the T-cell response across all groups was 
greatest with ChAd/NVX, which might prove important in 
terms of durability of protection and protection against 
new SARS-CoV-2 variants.40 These data align with real-
world evidence of robust effectiveness of mixed schedules 
against disease.24–26 Together, these findings support use of 
the mixed schedules studied here in rapid and flexible 
global deployment of COVID-19 vaccines. Accordingly, 
these schedules should be widely recognised for travel and 
certification.
Consistent with our previous results, schedules 
containing at least one mRNA dose showed the greatest 
binding and neutralising antibody responses, with 
the heterologous mRNA vaccination studied (BNT/
m1273) generating a greater humoral immune response 
than the homologous BNT/BNT schedule. Given that 
m1273 contains an mRNA dose (100 µg) over three times 
that of BNT (30 µg), and that the m1273 containing 
Prime with ChAd Prime with BNT
ChAd/ChAd (n=47) ChAd/m1273 (n=48) ChAd/NVX (n=51) BNT/BNT (n=46) BNT/m1273 (n=48) BNT/NVX (n=49)
Live virus neutralising antibody (Victoria*), FRNT50
n 47 48 51 46 48 49
GMC 109 (70–168) 1684 (1313–2162) 432 (301–618) 1501 (1188–1896) 1883 (1546–2294) 1109 (805–1529)
GMR† Ref 16·9 (10·1–28·0) 4·2 (2·4–7·2) Ref 1·3 (1·0–1·8) 0·8 (0·6–1·2)
Live virus neutralising antibody (beta), FRNT50
n 47 48 51 46 48 49
GMC 25 (18–34) 376 (260–545) 109 (71–167) 405 (290–565) 603 (442–822) 451 (305–666)
GMR† Ref 15·8 (9·6–26·1) 4·2 (2·4–7·4) Ref 1·6 (1·0–2·5) 1·3 (0·8–2·2)
Live virus neutralising antibody (delta), FRNT50
n 47 48 51 46 48 49
GMC 41 (27–64) 672 (506–891) 153 (99–237) 697 (520–933) 873 (688–1107) 629 (444–891)
GMR† Ref 17·4 (10·2–29·5) 3·7 (2·0–6·9) Ref 1·3 (0·9–2·0) 1 (0·7–1·6)
Cellular response (wild-type, frozen samples), SFC per million PBMCs
n 44 47 50 44 44 46
GMC 41 (27–62) 100 (73–136) 160 (129–198) 35 (25–49) 71 (52–97) 20 (14–29)
GMR† Ref 2·9 (1·8–4·6) 4·5 (3·0–6·8) Ref 1·9 (1·2–3·0) 0·60 (0·4–1·0)
Cellular response (beta, frozen samples), SFC per million PBMCs
n 44 47 50 44 44 46
GMC 41 (28–60) 104 (77–141) 150 (120–187) 34 (23–48) 69 (52–92) 22 (17–30)
GMR† Ref 3·1 (2·0–4·7) 4·2 (2·9–6·0) Ref 2·0 (1·2–3·1) 0·72 (0·46–1·1)
Cellular response (delta, frozen samples), SFC per million PBMCs
n 44 47 50 44 44 46
GMC 35 (23–54) 102 (76–136) 155 (123–196) 36 (26–51) 64 (47–86) 19 (13–28)
GMR† Ref 3·4 (2·1–5·4) 5·0 (3·3–7·6) Ref 1·6 (1·0–2·5) 0·56 (0·3–0·9)
Data shown are geometric mean (95% CI), unless otherwise specified. BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA 
laboratory units. FRNT50=50% focus reduction neutralising antibody titre. GMC=geometric mean concentration. GMR=geometric mean ratio. m1273=mRNA-1273 vaccine, 
Moderna. NVX=NVXCoV2373 vaccine, Novavax. PBMCs=peripheral blood mononuclear cells. SFC=spot-forming cells. *A Wuhan-related strain isolated early in the 
pandemic from Australia. †The two-sided 95% CIs of GMRs were adjusted for study site, cohort, interval between first and second dose, and baseline immunogenicity.
Table 3: Summary of immunogenicity against variants of concern between heterologous and homologous prime-boost schedules at 28 days after boost 
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schedules (BNT/m1273 and ChAd/m1273) generated the 
two highest antibody concentrations observed across 
Com-COV and this study, this might reflect a greater 
humoral immunogenicity of m1273 when compared with 
BNT, rather than a specific benefit of mixing mRNA 
vaccines.8 It is interesting to note that in the groups 
receiving an NVX boost, there is a modest increase in 
antibody titres after day 7; although the samples’ size are 
small, this finding warrants further investigation.
The strongest cellular immune response was seen 
with heterologous ChAd-primed schedules. ChAd/NVX 
showed the highest cellular response as measured by 
IFN-γ ELISPOT, and is similar to that seen with ChAd/BNT 
at a 28 day boost interval.8 The ChAd/m1273 schedule also 
produced a substantial cellular response, whereas both 
heterologous and homologous mRNA schedules 
(BNT/m1273 and BNT/BNT) showed lower res ponses. 
Strikingly, the BNT/NVX schedule produced a response 
Figure 4: Severity of solicited local and systemic reactions in days 0–7 following boost vaccination by study arm as self-reported in participant electronic diaries
Data are (A) local at vaccination site and (B) systemic. The severity presented is the participant’s highest severity across 7 days after vaccination for each solicited adverse event. Fever was defined as 
mild if 38·0°C to <38·5°C, moderate if 38·5°C to <39°C, and severe if ≥39·0°C. Feverish was self-reported feeling of feverishness. For systemic symptoms, grading was classified as mild if easily tolerated 
with no limitation on normal activity; moderate if some limitation of daily activity; severe if unable to perform normal daily activity. BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 
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below that of all other schedules studied, suggesting 
important differences in the ability of adenoviral-vectored 
and mRNA vaccines to prime T cells for subsequent 
stimulation by protein antigens.
These data do not show any convincing evidence of 
additional benefit of mixed schedules in maintaining 
neutralising activity against variants of concern, beyond 
that conferred by greater neutralising activity against the 
Victoria strain—ie, the decrease in neutralising activity 
elicited by mixed and homologous schedules was broadly 
similar. However, for the BNT/NVX recipients, it is 
notable that the apparent differences in neutralising 
activity against Victoria were less evident when testing 
against beta and delta strains. Whether this result is an 
artefact of a relatively small sample size, or suggestive of 
better preservation of neutralisation against variants of 
concern for this schedule, this finding warrants further 
research. Consistent with previous work, the T-cell 
response was maintained across all variants of concern, 
regardless of the schedule.40
This study supports our previous finding of mixed 
adenoviral-vectored and mRNA COVID-19 vaccine 
schedules being more reactogenic than homologous 
schedules, consistent with other studies examining 
BNT/ChAd.13,41 Additionally, there was evidence of 
increased reactogenicity for the heterologous over the 
homologous mRNA schedule (BNT/m1273 vs BNT/BNT). 
This effect could be due to the mixing of different mRNA 
vaccines, or m1273 being more reactogenic than BNT, 
potentially consistent with higher mRNA dosage; 
however, it is not possible to differentiate these possible 
causes in our study. By contrast, there was no evidence of 
increased reactogenicity for the NVX containing 
schedules. Importantly, within the limits of the sample 
size of this study, none of the schedules raised any safety 
concerns.
While most high-income countries have completed 
two-dose primary courses of COVID-19 vaccinations in 
adults, these data remain extremely relevant to the 94% of 
people in low-income countries who are yet to receive 
any doses.1 Of the mixed schedules studied, perhaps the 
most relevant to these countries is the ChAd/NVX, given 
that neither of these vaccines require ultra-low 
temperature storage and the low cost of ChAd. NVX has 
recently been the subject of a WHO Emergency Use 
Licence and should become available under the COVAX 
scheme.42 Furthermore data for mixed schedules across 
platforms could help to inform the use of third-dose 
boosters, in addition with data from CoV-BOOST 
(ISRCTN12348322)43 and the recent work by Atmar and 
colleagues44 supporting use of mRNA vaccines for 
adenoviral-primed individuals. Such schedules could 
also allow avoidance of a second mRNA vaccine dose in 
adolescents, given concerns regarding myocarditis, and 
this hypothesis is being further studied in Com-COV3.45,46
This study has a number of limitations. The age range 
(50–78 years) and ethnicity (90·7% of participants primed 
with ChAd and 94·7% of those primed with BNT self-
identified as White) of the study cohort limit 
generalisability of the reactogenicity and immunology 
results to younger populations and people who are not of 
White ethnicity. These groups might be more likely to 
receive heterologous COVID-19 vaccine schedules as a 
primary course, given age-associated safety concerns 
with the use of ChAd, and logistic constraints in lower-
income regions.47 Any increased reactogenicity with 
heterologous regimes might be amplified in younger 
groups, as reported in studies of homologous vaccine 
schedules.48–51 As participants were recruited after 
community prime, this dose was not randomised, 
meaning that some caution is required when comparing 
ChAd versus BNT community-primed groups, especially 
as there were higher rates of comorbidity in the 
BNT-primed groups. Additionally, the proportion of 
participants primed with ChAd versus BNT differed 
according to site, creating the potential for different 
amounts of exposure to SARS-CoV-2 between the groups. 
This fact is especially important when comparing the 
number of breakthrough infections observed between 
ChAd-primed and BNT-primed groups. Due to logistical 
and pragmatic constraints, we were not able to 
incorporate a full comparative schedule for all vaccines, 
and thus cannot provide evidence for the use of mixed 
mRNA schedules in both permutations, nor the effect of 
prime with a protein-based vaccine followed by ChAd or 
mRNA.
This research confirms previous evidence of mixed 
adenoviral and mRNA schedules as being safe, tolerable, 
and immunogenic alternatives to homologous schedules 
when given at an 8–12 weeks interval. It also provides 
new evidence on the response to mixed mRNA 
vaccinations in a randomised trial, and novel data for 
the incorporation of protein-based COVID-19 vaccines 
into heterologous schedules. These results provide 
reassurance that there are multiple appropriate options 
to complete primary immunisation in individuals primed 
with BNT or ChAd, which will facilitate rapid vaccine 
deployment globally.
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